Improving Treatment of HER2-Positive Cancers: Opportunities and Challenges

被引：107

作者：

Stern, Howard M. ^{[1
]}

机构：

[1] Genentech Inc, Dept Pathol Res, San Francisco, CA 94080 USA

来源：

SCIENCE TRANSLATIONAL MEDICINE | 2012年 / 4卷 / 127期

关键词：

GROWTH-FACTOR RECEPTOR; HER2-OVEREXPRESSING BREAST-CANCER; TRASTUZUMAB PLUS DOCETAXEL; KINASE INHIBITOR; OPEN-LABEL; ADJUVANT CHEMOTHERAPY; MONOCLONAL-ANTIBODY; ANTITUMOR-ACTIVITY; COMPLEX-FORMATION; GASTRIC-CANCER;

D O I：

10.1126/scitranslmed.3001539

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Amplification of the ERBB2 gene, which encodes human epidermal growth factor receptor 2 (HER2), causes the overexpression of a major proliferative driver for a subset of breast and gastric cancers. Treatments for patients with HER2-positive cancer include the monoclonal antibody trastuzumab and, in the case of metastatic breast cancer, the tyrosine kinase inhibitor lapatinib. Despite significant improvement in patient outcome as a result of these therapies, challenges remain. This Review focuses on proposed mechanisms of action and resistance in the context of potential new therapeutic options. Therapeutic approaches currently in development likely will yield additional clinically meaningful improvements for patients with HER2-positive cancer.

引用

页数：10

共 60 条

[41] Acceptance of Biomarker-Based Tests for Application in Clinical Practice: Criteria and Obstacles [J].

Pirmohamed, M. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (06) :862-866

[42] Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase [J].

Rabindran, SK ;

Discafani, CM ;

Rosfjord, EC ;

Baxter, M ;

Floyd, MB ;

Golas, J ;

Hallett, WA ;

Johnson, BD ;

Nilakantan, R ;

Overbeek, E ;

Reich, MF ;

Shen, R ;

Shi, XQ ;

Tsou, HR ;

Wang, YF ;

Wissner, A .

CANCER RESEARCH, 2004, 64 (11) :3958-3965

[43] Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer [J].

Romond, EH ;

Perez, EA ;

Bryant, J ;

Suman, VJ ;

Geyer, CE ;

Davidson, NE ;

Tan-Chiu, E ;

Martino, S ;

Paik, S ;

Kaufman, PA ;

Swain, SM ;

Pisansky, TM ;

Fehrenbacher, L ;

Kutteh, LA ;

Vogel, VG ;

Visscher, DW ;

Yothers, G ;

Jenkins, RB ;

Brown, AM ;

Dakhil, SR ;

Mamounas, EP ;

Lingle, WL ;

Klein, PM ;

Ingle, JN ;

Wolmark, N .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16) :1673-1684

[44] HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing [J].

Rueschoff, Josef ;

Dietel, Manfred ;

Baretton, Gustavo ;

Arbogast, Susanne ;

Walch, Axel ;

Monges, Genevieve ;

Chenard, Marie-Pierre ;

Penault-Llorca, Frederique ;

Nagelmeier, Iris ;

Schlake, Werner ;

Hoefler, H. ;

Kreipe, H. H. .

VIRCHOWS ARCHIV, 2010, 457 (03) :299-307

[45] p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer [J].

Sáez, R ;

Molina, MA ;

Ramsey, EE ;

Rojo, F ;

Keenan, EJ ;

Albanell, J ;

Lluch, A ;

García-Conde, J ;

Baselga, J ;

Clinton, GM .

CLINICAL CANCER RESEARCH, 2006, 12 (02) :424-431

[46] Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity [J].

Scaltriti, M. ;

Verma, C. ;

Guzman, M. ;

Jimenez, J. ;

Parra, J. L. ;

Pedersen, K. ;

Smith, D. J. ;

Landolfi, S. ;

Ramon y Cajal, S. ;

Arribas, J. ;

Baselga, J. .

ONCOGENE, 2009, 28 (06) :803-814

[47] Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer [J].

Scaltriti, Maurizio ;

Rojo, Federico ;

Ocana, Alberto ;

Anido, Judit ;

Guzman, Marta ;

Cortes, Javier ;

Di Cosimo, Serena ;

Matias-Guiu, Xavier ;

Ramon y Cajal, Santiago ;

Arribas, Joaquin ;

Baselga, Jose .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (08) :628-638

[48] Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients [J].

Scaltriti, Maurizio ;

Eichhorn, Pieter J. ;

Cortes, Javier ;

Prudkin, Ludmila ;

Aura, Claudia ;

Jimenez, Jose ;

Chandarlapaty, Sarat ;

Serra, Violeta ;

Prat, Aleix ;

Ibrahim, Yasir H. ;

Guzman, Marta ;

Gili, Magui ;

Rodriguez, Olga ;

Rodriguez, Sonia ;

Perez, Jose ;

Green, Simon R. ;

Mai, Sabine ;

Rosen, Neal ;

Hudis, Clifford ;

Baselga, Jose .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (09) :3761-3766

[49] Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor [J].

Scaltriti, Maurizio ;

Chandarlapaty, Sarat ;

Prudkin, Ludmila ;

Aura, Claudia ;

Jimenez, Jose ;

Davide Angelini, Pier ;

Sanchez, Gertrudis ;

Guzman, Marta ;

Lluis Parra, Josep ;

Ellis, Catherine ;

Gagnon, Robert ;

Koehler, Maria ;

Gomez, Henry ;

Geyer, Charles ;

Cameron, David ;

Arribas, Joaquin ;

Rosen, Neal ;

Baselga, Jose .

CLINICAL CANCER RESEARCH, 2010, 16 (09) :2688-2695

[50] Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models [J].

Scheuer, Werner ;

Friess, Thomas ;

Burtscher, Helmut ;

Bossenmaier, Birgit ;

Endl, Josef ;

Hasmann, Max .

CANCER RESEARCH, 2009, 69 (24) :9330-9336

← 1 2 3 4 5 6 →